Movatterモバイル変換


[0]ホーム

URL:


Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Actions

Share

Review
.2006 Nov;6(6):490-5.
doi: 10.1007/s11910-006-0051-6.

Psychotropic medication use for behavioral symptoms of dementia

Affiliations
Review

Psychotropic medication use for behavioral symptoms of dementia

Philip S Wang et al. Curr Neurol Neurosci Rep.2006 Nov.

Abstract

Behavioral disturbances associated with dementia are common and burdensome. Although no psychotropic medications are currently approved by the US Food and Drug Administration (FDA) to treat such behavioral symptoms, a variety of drug classes are commonly used for these purposes. Atypical antipsychotic medications may be somewhat effective and are generally considered the pharmacologic treatments of choice; however "black box" warnings have recently been added to their labels by the FDA, warning of significantly increased risks of short-term mortality. Older conventional antipsychotic medications may also be somewhat effective but appear to pose risks that can be at least as great as those of the newer atypical drugs. Although antidepressants, benzodiazepines, mood stabilizers, acetylcholinesterase inhibitors, and N-methyl-D-aspartate (NMDA) receptor antagonists may be considered, particularly in patients with specific types of symptomatology, even less is known about their effectiveness and safety. Also, although various psychotropic medications used for behavioral disturbances in dementia patients may be somewhat effective, they have been increasingly associated with important safety risks.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Am J Psychiatry. 2001 Nov;158(11):1774-82 - PubMed
    1. CNS Spectr. 2005 Nov;10(11 Suppl 18):22-5 - PubMed
    1. JAMA. 2005 May 25;293(20):2462 - PubMed
    1. Psychiatr Serv. 2002 Nov;53(11):1402-6 - PubMed
    1. Arch Neurol. 2003 Aug;60(8):1119-22 - PubMed

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.


[8]ページ先頭

©2009-2025 Movatter.jp